# Mesh Complications in Prolapse Surgery

> Vaginal mesh complications — erosion, pain, FDA 2019 withdrawal, mid-urethral sling status — NEET-PG Obstetrics and Gynaecology exam notes.

- Canonical URL: https://prepelephant.com/topics/neet-pg/obstetrics-and-gynaecology/mesh-complications-prolapse
- Exam / course: NEET-PG · Subject: Obstetrics and Gynaecology
- Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team
- First published: 2026-10-02
- Last updated: 2026-10-02
- How to cite: "Mesh Complications in Prolapse Surgery", PrepElephant, https://prepelephant.com/topics/neet-pg/obstetrics-and-gynaecology/mesh-complications-prolapse

## Direct answer

In April 2019 the US FDA ordered all manufacturers to stop selling transvaginal mesh for pelvic organ prolapse, concluding that the risk-benefit balance for prolapse mesh — erosion rates around 10 per cent, chronic pain, dyspareunia, and multi-revision surgery — was unfavourable; the United Kingdom had already paused its use in 2017 following the Cumberlege review's findings of avoidable harm. The critical discriminating fact for exams and counselling is that this withdrawal applies to transvaginal prolapse mesh, not to mid-urethral slings for stress urinary incontinence, which remain a recommended first-line surgical treatment, nor automatically to abdominal sacrocolpopexy mesh, which continues in selected apical cases. Complication recognition follows a pattern: vaginal erosion or exposure (mesh visible or palpable through vaginal epithelium), pain including dyspareunia and partner-related complaints, bladder or urethral and rarely bowel injury, infection or granulation, and recurrence; management escalates from topical oestrogen for small asymptomatic exposures to partial or complete mesh excision in a specialist centre.

## What you must remember

- **Timeline to quote:** transvaginal polypropylene prolapse kits multiplied through the 2000s; the FDA issued warnings in 2008 and 2011; Scotland (2014) and England (2017, Cumberlege/Baroness review "First Do No Harm", 2020) paused use; the FDA ordered market withdrawal of transvaginal POPS mesh in April 2019.
- **The classic complication figures:** vaginal mesh exposure/erosion after transvaginal prolapse mesh around 10 per cent (versus roughly 2-4 per cent for sacrocolpopexy mesh), with pelvic pain, dyspareunia and recurrence completing the cluster;erosions declare themselves most often within the first two years.
- **Exclusion that everyone tests:** mid-urethral slings (retropubic TVT, transobturator, single-incision) for stress incontinence were not withdrawn — their benefit-risk balance remains favourable and international guidelines continue to endorse them, with counselling about mesh-specific risks including 1-5 per cent vaginal erosion and voiding dysfunction.
- **Clinical presentation set:** persistent vaginal discharge or bleeding, dyspareunia (patient or partner feeling the mesh), recurrent urinary infection, pain on examination with palpable tape or arms, and extrusion into bladder (recurrent UTI, haematuria) or rarely rectum.
- **Classification:** complications are graded with systems adapted from Clavien-Dindo in UK practice; the older PROSPER terminology grouped complications by viscera and severity — useful viva vocabulary.
- **Management ladder:** small (<0.5 cm) asymptomatic exposures — topical oestrogen plus observation; symptomatic exposure — oestrogen then partial excision; pain, fistula or intravesical mesh — referral to a specialist mesh centre for partial or total excision, accepting that complete removal risks organ injury and may not abolish pain.
- **Medicolegal reality:** mesh litigation (thousands of claims against manufacturers globally, and consumer claims in Indian courts as well) means documented preoperative counselling — including mesh-specific consent covering erosion, pain, and the alternative native-tissue and non-surgical options — is now standard of care.
- **Safe practice now:** native-tissue repair is the default for transvaginal prolapse surgery; mesh restricted to selected recurrent apical prolapse via the abdominal route in centres with expertise.

## A typical exam case

A 55-year-old presents three years after transvaginal mesh prolapse surgery abroad with postmenopausal spotting, dyspareunia "like a pin inside", and recurrent urinary infection. Walk the assessment: examine with a small speculum — a 1 cm area of exposed white polypropylene at the vaginal apex, surrounding granulation, and palpable mesh arms in the obturator foramen tender to touch. Cystoscopy excludes intravesical tape; urine culture treats the current infection. The conversation follows the ladder: topical oestrogen for eight weeks (some small exposures re-epithelialise), nipping granulation, and — because pain persists — referral to a specialist mesh centre for partial excision of the exposed segment and arms, with explicit counselling that pain relief is probable but not guaranteed and that total excision carries bladder and ureteric risk. If cystoscopy had shown intravesical mesh with calculus, the plan becomes surgical removal by the appropriate route regardless of symptoms. Every step of that paragraph is a separate mark scheme line: recognition, organ assessment, conservative trial, referral threshold, and honest expectation-setting.

## How the exam frames it

Two question families dominate. The first is the discrimination: "which mesh procedure was withdrawn" — transvaginal prolapse mesh, not mid-urethral slings and not (automatically) sacrocolpopexy; candidates who answer "all mesh banned" fail the nuance the examiner planted. The second is management of exposure: the tiny asymptomatic exposure gets oestrogen, not theatre; the painful or large exposure gets excision; intravesical tape always gets surgery. A third, quieter layer tests consent law and counselling — the FDA date (2019) and the UK pause/Cumberlege review have appeared as one-liners, and "documented discussion of native-tissue alternatives" is the defensible answer to "how do you consent for a sling today". Indian-practice context: mesh kits remain accessible and are still used variably across centres, so the examinable Indian answer is not "mesh is unavailable" but "transvaginal prolapse mesh is disfavoured by current evidence, native tissue is the default, and sling mesh for stress incontinence continues with informed consent".

## Frequently asked questions

### Which mesh procedures were withdrawn by the FDA in 2019?

Transvaginal mesh kits for pelvic organ prolapse repair — not mid-urethral slings for stress urinary incontinence, which remain guideline-endorsed first-line surgery.

### What is the commonest mesh complication after transvaginal prolapse repair?

Vaginal erosion or exposure, occurring in roughly 10 per cent, typically presenting with discharge, bleeding, dyspareunia or pain within the first two years.

### How is a small asymptomatic mesh exposure managed?

With topical oestrogen and observation first — small exposures can re-epithelialise — reserving excision for persistence, symptoms or larger defects.

### Can mesh complications cause urinary symptoms?

Yes — extrusion or intravesical mesh causes recurrent urinary infection, haematuria and dysuria, with cystoscopy the diagnostic step and surgery the treatment for intravesical tape.

### Is sacrocolpopexy mesh still used?

Yes — abdominal (open or laparoscopic) sacrocolpopexy with mesh remains an option for selected recurrent or advanced apical prolapse, with erosion rates lower (roughly 3-5 per cent) than the withdrawn transvaginal kits.